TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
IRVINE, Calif., April 19, 2016 -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its first quarter 2016 financial results, which will take place on Monday, May 9, 2016 after the close of the market.
Endologix will hold a conference call on Monday, May 9, 2016 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results. The dial-in numbers are (877) 407-0789 for domestic callers and (201) 689-8562 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.endologix.com.
After the live webcast, a replay of the webcast will remain available online from the investor relations page of Endologix's website, www.endologix.com, through May 9, 2017. In addition, a transcript will be posted to website and a telephonic replay of the call will be available until May 16, 2016. The replay dial-in numbers are (877) 870-5176 for domestic callers and (858) 384-5517 for international callers. Please use the replay pin number 13634655.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.
ENDOLOGIX CONTACT: Endologix, Inc. John McDermott, CEO Vaseem Mahboob, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico (646) 536-7030 Zack Kubow (646) 536-7020
